Eisai expects that Leqembi, which is for Alzheimer's, is going to be a trillion dollar product. Lenvima is working on a major foray in combination with Merck's Keytruda into lung cancer.

Eisai: Looking To Upside Targets Following Leqembi Full Approval Jul. 09, 2023 10:00 AM ET Eisai Co., Ltd. (ESAIY) Stock , ESALF Stock BIIB , ESAIY , ESALF 5 Comments 2 Likes Zach Bristow ...

Eisai now expects Leqembi sales to total JPY 42.5 billion (approximately SEK 3 billion) for the period, down from JPY 56.5 billion announced in May.

--BioArctic AB's partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion for their fiscal year 2025, corresponding to a 73 percent growth compared to the previous year.

Patients who started Leqembi early continued to benefit from the drug over three years, showing a slower rate of cognitive decline compared to the other two groups, according to an Eisai presentation.

Update on LEQEMBI Investigational Subcutaneous FormulationTOKYO, Oct. 15, 2023 /PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Nait ...

Leqembi, sold by partners Eisai Co Ltd , opens new tab and Biogen Inc , opens new tab at an annual list price of $26,500, was approved this year under the U.S. Food and Drug Administration's ...

Eisai, which leads Leqembi efforts, first planned to start a rolling submission in March as it collects the additional data. But the FDA told the company that a fast-track designation for the ...

STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK ...

STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK ...